New immunotherapy agent prolongs survival of men with advanced prostate cancer
This article has no abstract so we have provided the first paragraph of the full text.
Men with advanced prostate cancer have a very limited life expectancy, and the few treatment options available are often accompanied by severe adverse effects. A new class of immunotherapeutic agents based on modified autologous antigen-presenting cells is being developed; these stimulate the patient's own cellular immunity and have minimal toxicity. Promising results have been reported from a phase III trial of one such agent, sipuleucel-T, which targets prostatic acid phosphatase, a prostate-cancer-specific antigen.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
A new lease on life for dendritic cell vaccines?Nature Biotechnology News and Views (01 Dec 2006)